Cargando…

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment

Nitisinone (NIT) causes tyrosinaemia and corneal keratopathy (KP), especially in men. However, the adaptation within the phenylalanine (PHE)/tyrosine (TYR) catabolic pathway during KP is not understood. The objective of this study is to assess potential differences in the PHE/TYR pathway during KP a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranganath, Lakshminarayan R., Milan, Anna M., Hughes, Andrew T., Davison, Andrew S., Khedr, Milad, Imrich, Richard, Rudebeck, Mattias, Olsson, Birgitta, Norman, Brendan P., Bou-Gharios, George, Gallagher, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416442/
https://www.ncbi.nlm.nih.gov/pubmed/36005644
http://dx.doi.org/10.3390/metabo12080772
_version_ 1784776481208008704
author Ranganath, Lakshminarayan R.
Milan, Anna M.
Hughes, Andrew T.
Davison, Andrew S.
Khedr, Milad
Imrich, Richard
Rudebeck, Mattias
Olsson, Birgitta
Norman, Brendan P.
Bou-Gharios, George
Gallagher, James A.
author_facet Ranganath, Lakshminarayan R.
Milan, Anna M.
Hughes, Andrew T.
Davison, Andrew S.
Khedr, Milad
Imrich, Richard
Rudebeck, Mattias
Olsson, Birgitta
Norman, Brendan P.
Bou-Gharios, George
Gallagher, James A.
author_sort Ranganath, Lakshminarayan R.
collection PubMed
description Nitisinone (NIT) causes tyrosinaemia and corneal keratopathy (KP), especially in men. However, the adaptation within the phenylalanine (PHE)/tyrosine (TYR) catabolic pathway during KP is not understood. The objective of this study is to assess potential differences in the PHE/TYR pathway during KP and the influence of gender in NIT-induced tyrosinaemia in alkaptonuria (AKU). Samples of serum and 24 h urine collected from patients treated with NIT during a 4-year randomized study in NIT vs. no-treatment controls (SONIA 2; Suitability Of Nitisinone In Alkaptonuria 2; EudraCT no. 2013-001633-41) at months 3 (V2), 12 (V3), 24 (V4), 36 (V5) and 48 (V6) were included in these analyses. Homogentisic acid (HGA), TYR, PHE, hydroxyphenylpyruvate (HPPA), hydroxyphenyllactate (HPLA) and sNIT were analysed at all time-points in serum and urine in the NIT-group. All statistical analyses were post hoc. Keratopathy occurred in 10 out of 69 AKU patients, eight of them male. Thirty-five sampling points (serum and 24 h urine) were analysed in patients experiencing KP and 272 in those with no-KP (NKP) during NIT therapy. The KP group had a lower HPLA/TYR ratio and a higher TYR/PHE ratio compared with the NKP group (p < 0.05 for both). There were 24, 45, 100 and 207 sampling points (serum and 24 h urine) in the NIT group which were pre-NIT female, pre-NIT male, NIT female and NIT male, respectively. The PHE/TYR ratio and the HPLA/TYR ratio were lower in males (p < 0.001 and p < 0.01, respectively). In the KP group and in the male group during NIT therapy, adaptive responses to minimise TYR formation were impaired compared to NKP group and females, respectively.
format Online
Article
Text
id pubmed-9416442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94164422022-08-27 Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment Ranganath, Lakshminarayan R. Milan, Anna M. Hughes, Andrew T. Davison, Andrew S. Khedr, Milad Imrich, Richard Rudebeck, Mattias Olsson, Birgitta Norman, Brendan P. Bou-Gharios, George Gallagher, James A. Metabolites Article Nitisinone (NIT) causes tyrosinaemia and corneal keratopathy (KP), especially in men. However, the adaptation within the phenylalanine (PHE)/tyrosine (TYR) catabolic pathway during KP is not understood. The objective of this study is to assess potential differences in the PHE/TYR pathway during KP and the influence of gender in NIT-induced tyrosinaemia in alkaptonuria (AKU). Samples of serum and 24 h urine collected from patients treated with NIT during a 4-year randomized study in NIT vs. no-treatment controls (SONIA 2; Suitability Of Nitisinone In Alkaptonuria 2; EudraCT no. 2013-001633-41) at months 3 (V2), 12 (V3), 24 (V4), 36 (V5) and 48 (V6) were included in these analyses. Homogentisic acid (HGA), TYR, PHE, hydroxyphenylpyruvate (HPPA), hydroxyphenyllactate (HPLA) and sNIT were analysed at all time-points in serum and urine in the NIT-group. All statistical analyses were post hoc. Keratopathy occurred in 10 out of 69 AKU patients, eight of them male. Thirty-five sampling points (serum and 24 h urine) were analysed in patients experiencing KP and 272 in those with no-KP (NKP) during NIT therapy. The KP group had a lower HPLA/TYR ratio and a higher TYR/PHE ratio compared with the NKP group (p < 0.05 for both). There were 24, 45, 100 and 207 sampling points (serum and 24 h urine) in the NIT group which were pre-NIT female, pre-NIT male, NIT female and NIT male, respectively. The PHE/TYR ratio and the HPLA/TYR ratio were lower in males (p < 0.001 and p < 0.01, respectively). In the KP group and in the male group during NIT therapy, adaptive responses to minimise TYR formation were impaired compared to NKP group and females, respectively. MDPI 2022-08-22 /pmc/articles/PMC9416442/ /pubmed/36005644 http://dx.doi.org/10.3390/metabo12080772 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ranganath, Lakshminarayan R.
Milan, Anna M.
Hughes, Andrew T.
Davison, Andrew S.
Khedr, Milad
Imrich, Richard
Rudebeck, Mattias
Olsson, Birgitta
Norman, Brendan P.
Bou-Gharios, George
Gallagher, James A.
Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
title Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
title_full Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
title_fullStr Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
title_full_unstemmed Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
title_short Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
title_sort comparing the phenylalanine/tyrosine pathway and related factors between keratopathy and no-keratopathy groups as well as between genders in alkaptonuria during nitisinone treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416442/
https://www.ncbi.nlm.nih.gov/pubmed/36005644
http://dx.doi.org/10.3390/metabo12080772
work_keys_str_mv AT ranganathlakshminarayanr comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT milanannam comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT hughesandrewt comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT davisonandrews comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT khedrmilad comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT imrichrichard comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT rudebeckmattias comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT olssonbirgitta comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT normanbrendanp comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT boughariosgeorge comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment
AT gallagherjamesa comparingthephenylalaninetyrosinepathwayandrelatedfactorsbetweenkeratopathyandnokeratopathygroupsaswellasbetweengendersinalkaptonuriaduringnitisinonetreatment